account adjust acquisition-rel cost certain
signific item
conjunct model note issu today detail implic
sale ep estim ep estim rais power
keytruda project top temper keytruda impact
product declin pipelin limit visibl remain market perform
pend visibl total revenu growth outlook
ep estim intact vs consensu
vs consensu ep forecast increas vs
previous consensu vs previous
consensu vs previous ep
compound-annual-growth-rate vs previous mrk growth consist
industri averag despit keytruda huge success given enhanc growth
outlook rais target price ep
sale estim lower vs consensu
vs consensu
thereaft forecast rais significantli sale forecast increas
vs consensu vs
consensu vs previous
sale compound-annual-growth-rate vs previous
keytruda sale estim roughli intact thereaft
estim rais
biggest contributor higher keytruda sale nsclc melanoma
rcc
oper margin estim intact oper margin forecast
rais
howev project lower
project compound consist sale expans
sg grow oper expens growth overal
pleas see page report import disclosur
merck competit posit line lung cancer clear posit merck face
uncertainti includ januvia outlook competit market competit pressur
isentress zostavax thin pipelin believ risk balanc opportun
therefor remain market perform stock
uptak keytruda nsclc
keytruda data readout variou tumor
keytruda approv merkel cell
lynparza approv ovarian cancer
oper margin improv
expect
new product unabl off-set januvia
zetia cubicin patent expir
competit pressur zostavax
merck global health care compani includ prescript medicin vaccin
biolog therapi anim health strong product presenc oncolog
cardiovascular anti-infect anti-inflammatori diabet area among other
anim health divis focus mainli feed anim
cowen compani
totalgrosssg aoper non-pretaxtaxnety/ysharessal chgp mm sl mm slsp opp rateincomeep restat defin benefit cost present outsid oper expens reflect non-op income/expens cowen
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
cowen compani
 patent expir glenmark enter month exclusivityzetia patent expir gener launch ezetimibecozaar/hyzaar arb hypertens gener competitionvytorin exclus laps patent expir lost patent case euvytorin ezetimibe/simvastatin improve-it achiev endpoint garner fda labelintegrilin revenu repurchas milleniumzocor cholesterol reduct patent expir develop riociguat solubl guanyl cyclas sgc modul approv eu pah cteph japan zetia lipitor market eu market phase heart failur victoria ref-hf primari complet januari part bayer patent expir littl eros japan despit patent market bridion market eu japan eu patent exp sugammadex anesthesia revers suvorex insomnia orexin neuropeptid approv us japan yet file eu schizophrenia phase iiremeron antidepress patent expir januari major sale ex-u maxalt/maxalt mlt patent expir maxalt/maxalt mlt patent expir eumaxalt/maxalt mlt agonist anesthesia patent expir cowen
cowen compani
 qd market blunt erosionisentress qd approv eu hiv integras inhibitor treatment resist nave approv gilead gsk tivicay pose competitionnoxafil patent expir eu patent expir posaconazol oral antifung approv prophylaxi oral candidiasi cubicin advers court decis allow gener first gener teva launch sale nv modest royaltiescubicin cubist acquir launch competit landscap pressureszepati launch eu japan competit landscap pressureszepati hepat grazoprevir proteas inhibitor elbasvir competit landscap ceftolozane/tazobactam ww right ex asia-pacif gram neg infect phase habp/vabp bezlotoxumab tx difficil associ diarrhea cdad approv medarex/ma biolog difficil cubistpifeltro mono /delstrigo doravirin nnrti hiv qd dose approv letermovir cmv prophylaxi transplant patient roll-out tedizolid gram po infect launch phase habp/vabp hiv infect phase relebactam imipenem/cilastatin bacteri infect phase file roch pegasys/copegu pressur new drug clip durat therapyintron support use oncolog applicationsribavirin/rebetol older modalityintron substanc patent exp formul patent exp settlement allow gener launch aug ou patent expiredcancida antifung qd iv new indic price share eros due competitioninvanz patent expir compound composit gener launch broad spectrum carbapenem oral im iv qdprimaxin emerg market-drivenprimaxin bolster sale effort blunt eros patent expir proteas inhibitor aid stocrin certain fgn mkt patent exp older antibioticstot cowen
cowen compani
 golimumab ra pa uc approv eu canada competit clip growtharcoxia approv market countriesremicad crohn uc ra pa earli ra psoriasi patent expir biosimilar exposur marketstot approv tumor type includ melanoma lung chl bladder msi-hkeytruda eu approv melanoma lung chl bladderkeytruda antibodi mani tumor type melanoma phase saha cutan t-cell lymphoma roll-out underway clinic trial underwayemend aprepit substanc antagonist emesi patent exp oral iv franchis oral/ivtemodar teva launch gener gener japan pat exp eu temodar chemotherapeut aa gbmazn lynparza/selumetinib record sale net cog sg record lineeisai lenvima record sale net cog sg record linetot gener launch over-the-counter product also pressurenasonex gener eu allerg rhinitisdulera asthma market copd longer pursu dulera launch copd four market asthma market dulera mometasone/formoterol ics/laba twice daili competit pressuressingulair patent expir patent expir eu includ month pedi exclus japansingulair chronic acut cough includ idiopath pulmonari fibrosi pain migrain endometriosi phase iiiasmanex market asmanex market countriesasmanex asthma dri powder qd inhal corticosteroid patent devic formul expir beta agonist asthma cfc hfa complet cowen
cowen compani
 continuedclarinex small market retainedclarinex claritin rx/otc sold bayer ag tax part consum transact close claritin/clarinex asthma older product europetot nrx share patent expir pedi exclus could add monthsjanuvia patient expir exclus could add month januvia qd antidiabet competit threat given proven cv ertugliflozin diabet inhib w/ app mono combo w/sitagliptin metformin insulin glargin biosimilar approv eu launch time unclear omarigliptin diabet qweek inhibitor market japan file plan diabet mellitu dual agonist antibodi phase ii clinic holdtot competit gsk shingrix prompt zostavax declin sale reflect dissolut spmsd jv ad herp zoster vaccin adult year singl sq dose plu booster investigatedproquad mmr ii varivax mmr ii varivax sale reflect dissolut spmsd jv ad mmr ii varivax could support health initiativesrotateq sale reflect dissolut spmsd jv ad rotaviru vaccin oral liquid good safeti profil market ww competit gskgardasil/gardasil approv year old femal male sale gardasil two dose approv fda/cdcgardasil/gardasil sale reflect dissolut spmsd jv ad approv two dose regimen china launch boostsgardasil/gardasil hpv vaccin borrow cdc stockpil refil hexaval combin pediatr vaccin approv eu issu refil pneumoconjug vaccin phase valent tough competit cytomegaloviru vaccin phase inactiv herp zoster vaccin phase develop hold due competit environmentpneumovax use dose post prevnar boost tie birth cohortpneumovax support integr spmsd jv marketspneumovax pneumococc vaccin adultstot cowen
cowen compani
 psoriasi moder potenc steroid patent exp compound cream lotion implanon/nexplanon patent expir patent expir implant contracept patent expir juli progesteron/estrogen market eu exclus pursu corifollitropin alpha infertil market eu exclus pursu nuvar patent expir april gener yet launchednuvar contracept vagin contracept patent expir septemb aq aq aq follitropin beta inject patent expir june oral contracept patent expir decemb contracept patent expir septemb oral contracept patent expir march contraception/women cowen
cowen compani
 bph gener competit fosamax osteoporosi gener launch patent expir bald domin small acceler time upper lower gi recoveri post surgeri gener competit prompt declineastra merck nmnm merck/oth suppli sale plu royaltypharmaceut ingredients/diversifi brandsnmnm api revenue product diversifi brand revenue divest aspenoth ivomec merial othertot healthlivestock leader vaccinescompanion anim bravecto oral approv may key driver line extens launchinganim boost smaller acquisitionscompanion anim bravecto numer therapeut productsanim estim anim market growth guidanc anim health segment sale cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl januvia vytorin
zetia isentress success pipelin product especi suvorex odanacatib
anacetrapib lambrolizumab success deal patent litig patent
expir pressur binari risk includ safeti issu involv odanacatib
improve-it studi vytorin
